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AbsTRACT
background exposure to radiation and/or 
chemotherapy during cancer treatment can compromise 
respiratory function. We investigated the risk of 
long-term respiratory mortality among 5-year cancer 
survivors diagnosed before age 40 years using the British 
childhood cancer Survivor Study (BccSS) and teenage 
and Young adult cancer Survivor Study (tYacSS).
Methods the BccSS comprises 34 489 cancer survivors 
diagnosed before 15 years from 1940 to 2006 in great 
Britain. the tYacSS includes 200 945 cancer survivors 
diagnosed between 15 years and 39 years from 1971 to 
2006 in england and Wales. Standardised mortality ratios 
and absolute excess risks were used.
Findings Overall, 164 and 1079 respiratory deaths 
were observed in the BccSS and tYacSS cohorts 
respectively, which was 6.8 (95% ci 5.8 to 7.9) and 1.7 
(95% ci 1.6 to 1.8) times that expected, but the risks 
varied substantially by type of respiratory death. greatest 
excess numbers of deaths were experienced after central 
nervous system (cnS) tumours in the BccSS and after 
lung cancer, leukaemia, head and neck cancer and cnS 
tumours in the tYacSS. the excess number of respiratory 
deaths increased with increasing attained age, with 
seven (95% ci 2.4 to 11.3) excess deaths observed 
among those aged 50+ years in the BccSS and three 
(95% ci 1.4 to 4.2) excess deaths observed among those 
aged 60+ years in the tYacSS. it was reassuring to see 
a decline in the excess number of respiratory deaths 
among those diagnosed more recently in both cohorts.
Conclusions Prior to this study, there was almost 
nothing known about the risks of respiratory death after 
cancer diagnosed in young adulthood, and this study 
addresses this gap. these new findings will be useful 
for both survivors and those involved in their clinical 
management and follow-up.
InTRoduCTIon
Survival after childhood, adolescent and young 
adult cancer has improved substantially over recent 
decades, with approximately 80% of those diag-
nosed now surviving at least 5 years.1 2 However, the 
curative treatments used to achieve such outcomes 
are associated with adverse health effects. One such 
adverse health effect concerns respiratory diseases 
(International Classification of Diseases (ICD) 10th 
revision: J00–J99) which, following circulatory 
diseases (ICD-10: I00–I99), account for the most 
non-neoplastic deaths among childhood cancer 
survivors.3 Previous research indicates that direct 
irradiation to the chest and lungs can cause devel-
opmental abnormalities of the thoracic cage, short-
term treatment-induced lung disease presenting as 
pneumonitis or interstitial lung injury, and long-
term damage manifesting as fibrosis.4 Furthermore, 
a number of chemotherapy drugs have been associ-
ated with respiratory late effects.4 5 Such respiratory 
morbidities can impact the quality of life of survi-
vors5 and lead to premature death. As the number 
of childhood, adolescent and young adult cancer 
survivors is growing, with all having a substantial 
proportion of their expected lifespan remaining, it 
is crucial to investigate the risk of respiratory late 
effects in this population of survivors in order to 
identify vulnerable subgroups who may require 
closer clinical follow-up or intervention, as well as 
to improve our understanding of the pathogenesis 
of respiratory complications so that such late effects 
can be prevented in the future.
We assessed the long-term risks of respirato-
ry-specific mortality among 5-year survivors of 
cancer diagnosed before the age of 40 years using 
Key messages
What is the key question?
 ► What are the long-term risks of respiratory-
specific mortality among 5-year survivors of 
childhood, adolescent and young adult cancer?
What is the bottom line?
 ► This large-scale population-based study 
provides evidence that such survivors are at 
an increased risk of respiratory death, with 
appreciable excesses observed among survivors 
of specific cancers and survivors aged over 
50 years, although there is evidence of a 
reduction in the excess number of respiratory 
deaths among individuals diagnosed recently.
Why read on?
 ► This article substantially advances the 
knowledge on respiratory mortality among 
childhood, adolescent and young adult cancer 
survivors by providing the most comprehensive 
analysis to date on respiratory mortality, which 
is useful for both survivors and those involved 
in their clinical follow-up.
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the British Childhood Cancer Survivor Study (BCCSS) and 
Teenage and Young Adult Cancer Survivor Study (TYACSS). With 
over 235 000 survivors, more than 1200 observed respiratory 
deaths, and nearly 3.5 million person-years available, this study 
is by far the largest ever assembled to assess long-term respira-
tory mortality in survivors of childhood, adolescent and young 
adult cancers. The findings presented provide evidence for respi-
ratory mortality risks overall, as well as the risks of specific types 
of respiratory death. The evidence produced will be useful for 
both survivors and those involved in clinical management and 
follow-up of survivors.
MeThods
study populations
This study uses two of the largest population-based cohorts of 
childhood, adolescent and young adult cancer survivors: the 
BCCSS6 and TYACSS.7 The BCCSS comprises 34 489 5-year 
survivors of childhood cancer diagnosed under the age of 
15 years in Great Britain from 1940 to 2006. The cohort was 
identified using the National Registry of Childhood Tumors,8 
and all first primary neoplasms (FPN) were classified using the 
International Classification of Childhood Cancer (online supple-
mentary etable 1).9 The TYACSS includes 200 945 5-year survi-
vors of adolescent and young adult cancers diagnosed between 
1971 and 2006, in England and Wales, when aged between 15 
years and 39 years. The cohort was established in collabora-
tion with the Office for National Statistics and Welsh Cancer 
Registry. Adolescent and young adult FPNs were classified using 
the categories proposed by Birch et al, which were then slightly 
modified to produce finer groupings (online supplementary 
etable 2).10 11
death ascertainment
The BCCSS and TYACSS cohorts were linked to the National 
Death Registration systems in order to ascertain each survivor’s 
vital and emigration status. This linkage provided the death certif-
icate and underlying cause of death, as coded using the relevant 
ICD at time of death. Respiratory deaths were determined by 
using the ‘diseases of the respiratory system’ chapters of the rele-
vant ICD editions. ICD codes were further subcategorised into 
the following clinically relevant groups for analysis: pneumonia, 
chronic lower respiratory disease (excluding asthma), fibrosis, 
pneumonitis and other respiratory deaths (online supplemen-
tary etable 3). Follow-up for respiratory mortality commenced 
at 5-year survival and continued until the first occurrence of 
emigration, death or 28 February 2014.
statistical analyses
To investigate the risk of respiratory mortality among survi-
vors compared with that expected from the general population, 
standardised mortality ratios (SMRs) and absolute excess risks 
(AERs) were calculated using standard cohort techniques.12 
The SMR was defined as the ratio of the observed over the 
expected number of respiratory deaths. The AER was defined 
as the observed minus the expected number of respiratory 
deaths divided by person-years at risk multiplied by 10 000; 
when reporting AERs, we often simply provide the excess, or 
extra, number of deaths without specifying the 10 000 person-
years denominator. Expected numbers were calculated by multi-
plying the person-years at risk for each sex-specific, age-specific 
(5-year bands) and calendar year-specific (1-year bands) stratum 
by the corresponding respiratory mortality rate for the popula-
tion of England and Wales and then summing across the strata.13 
Likelihood ratio tests comparing multivariate Poisson regression 
models adjusting for the simultaneous effects of sex, FPN type, 
age at cancer diagnosis, treatment era and attained age were 
used to test for significant heterogeneity or a significant linear 
trend in the adjusted SMRs and AERs for each explanatory 
factor. In reporting, we focus on AERs because of their direct 
and clear interpretation as the excess number of deaths beyond 
that expected, indicating extent of adverse public health impact. 
All analyses were completed using Stata Corp, 2013 V.13.1, 
where the criterion for statistical significance was a two-sided 
P<0.05. 
Role of the funding source
The funder had no role in this study. The lead and corresponding 
authors had full access to all the data in the study and had final 
responsibility of the decision to submit for publication.
ResulTs
british Childhood Cancer survivor study
All respiratory deaths
The BCCSS cohort was followed up for a total of 620 758 person-
years from 5-year survival. The mean follow-up from FPN diag-
nosis was 23.0 years (range: 5.0–73.7) and mean attained age at 
the end of current follow-up was 29.6 years (range: 5.5–85.6). 
Of the 4475 deaths observed, 164 (3.7%) were due to respira-
tory causes (table 1). Over half of the respiratory deaths were 
observed in survivors of central nervous system (CNS) tumours, 
including CNS primitive neuroectodermal tumours (PNET). 
However, when the proportion of deaths attributable to respi-
ratory causes was assessed, germ cell tumour survivors had the 
highest percentage at nearly 11%.
Survivors of childhood cancer were 6.8 times (95% CI 5.8 to 
7.9) more at risk of respiratory death than expected in the general 
population; this equated to 2.3 (95% CI 1.8 to 2.7) excess respi-
ratory deaths (figure 1). Survivors of each FPN type with at least 
5 observed deaths were found to be significantly more at risk of 
respiratory death than expected; the excess number of respira-
tory deaths exceeded 5 among survivors of CNS PNET and CNS 
tumours (excluding PNET) at 7.7 (95% CI 3.6 to 11.7) and 5.1 
(95% CI 3.8 to 6.5), respectively. As attained age increased, the 
AERs increased (adjusted p trend=0.0127); at 5–19 years age, 
the AER was 1.7 (95% CI 0.3 to 3.1), while beyond 50 years 
age the AER was 6.8 (95% CI 2.4 to 11.3). Among those treated 
more recently, the number of excess respiratory deaths declined 
(adjusted p trend=0.0153); survivors diagnosed before 1970 
and between 1990 and 2006 experienced 3.4 (95% CI 2.3 to 
4.6) and 1.0 (95% CI 0.5 to 1.5) excess respiratory deaths, 
respectively.
Of the 164 respiratory deaths observed, there were 77 pneu-
monia, 18 pneumonitis, 15 fibrosis, 11 chronic lower respiratory 
disease and 43 other respiratory deaths (online supplementary 
etable 4). The corresponding SMRs were 8.2 (95% CI 6.5 to 
10.2), 16.9 (95% CI 10.0 to 26.8), 13.8 (95% CI 7.7 to 22.8), 
1.8 (95% CI 0.9 to 3.2) and 6.5 (95% CI 4.7 to 8.8), respec-
tively, and the corresponding AERs were 1.1 (95% CI 0.8 to 
1.4), 0.3 (95% CI 0.1 to 0.4), 0.2 (95% CI 0.1 to 0.3), 0.1 (95% 
CI 0.0 to 0.2) and 0.6 (95% CI 0.4 to 0.8). As nearly half of 
the respiratory deaths observed were due to pneumonia, further 
analyses were only undertaken for this specific group of deaths. 
However, it is worth noting that 13/18 (72.2%) of the pneu-
monitis deaths occurred in CNS tumours (excluding PNET) 
survivors, which equated to a 53.8-fold (95% CI 28.6 to 92.0) 
increased risk compared with that expected.
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Pneumonia deaths
Survivors of CNS PNET, CNS tumours (excluding PNET) and 
germ cell tumours experienced the greatest excess numbers of 
pneumonia deaths at 5.2 (95% CI 1.9 to 8.5), 2.8 (95% CI 1.8 
to 3.8) and 2.1 (95% CI 0.1 to 4.1), respectively (figure 2). 
With more recent treatment era, there was a decline in the 
excess number of pneumonia deaths observed (adjusted p trend 
<0.0001), where the AER decreased from 2.2 (95% CI 1.3 to 
3.0) to 0.1 (95% CI −0.1 to 0.2) among those diagnosed before 
1970 and between 1990 and 2006, respectively.
Teenage and Young Adult Cancer survivor study
All respiratory deaths
From 5-year survival, the TYACSS cohort was followed up for 
a total of 2 867 878 person-years. The mean follow-up from 
FPN diagnosis was 19.3 years (range: 5.0–43.2) and mean 
attained age at exit was 51.0 years (range: 20.3–82.7). Overall, 
34 180 (17.0%) adolescent and young adult survivors had died; 
of these, 1079 (3.2%) were due to respiratory causes (table 2). 
The proportion of deaths attributable to respiratory causes was 
highest among lung cancer survivors at 10%, followed by head 
and neck cancer survivors and cervical cancer survivors at 6% 
each.
Overall, adolescent and young adult survivors were 70% 
(SMR: 1.7; 95% CI 1.6 to 1.8) more likely to die from a respi-
ratory cause than expected from the general population, which 
equated to 1.5 (95% CI 1.3 to 1.7) excess respiratory deaths 
(figure 3). The excess number of respiratory deaths was signifi-
cantly higher among males compared with females (adjusted 
p heterogeneity=0.0210). Survivors of lung, leukaemia 
(excluding acute myeloid leukaemia (AML)), head and neck 
cancer and CNS tumours experienced the greatest excess 
number of respiratory deaths at 11.4 (95% CI 5.9 to 16.9), 5.0 
(95% CI 2.5 to 7.5), 4.8 (95% CI 1.5 to 8.1), 4.4 (95% CI 2.2 
to 6.6) and 4.3 (95% CI 3.3 to 5.3), respectively. As attained 
age increased. the AERs increased from 1.4 (95% CI 0.7 to 2.1) 
among those aged 20–29 years to 2.8 (95% CI 1.4 to 4.2) among 
those aged 60+ years (adjusted p trend=0.0001). A decline in 
the excess number of respiratory deaths with more recent treat-
ment era was observed (adjusted p trend=0.0146), where the 
AER decreased from 2.2 (95% CI 1.6 to 2.8) to 0.7 (95% CI 
0.3 to 1.1) in those treated in the 1970s and 2000s, respectively.
When the 1079 respiratory deaths were assessed by specific 
respiratory causes of death, there were 395 pneumonia, 393 
chronic lower respiratory disease, 74 fibrosis, 49 pneumonitis 
and 168 other respiratory deaths (figure 4, table 3). Although 
adolescent and young adult survivors were at a statistically 
significant increased risk of death from each specific type of 
respiratory death, the SMR was greatest for pneumonitis and 
pneumonia deaths at 2.2 (95% CI 1.6 to 2.9) and 2.1 (95% CI 
1.9 to 2.3), respectively.
Table 1 Study characteristics of the British Childhood Cancer 
Survivor Study
Patient characteristic
Respiratory 
death %
other 
death % Total
Overall 164 3.7 4311 96.3 4475
Sex
  Male 98 3.7 2531 96.3 2629
  Female 66 3.6 1780 96.3 1848
First primary neoplasm type
  CNS tumour (excluding 
PNET)
68 5.3 1223 94.7 1291
  CNS PNET 15 4.4 326 95.6 341
  Leukaemia (excluding 
AML)
23 2.1 1080 97.9 1103
  AML 3 3.7 79 96.3 82
  Hodgkin’s lymphoma 7 2.1 324 97.9 331
  Non-Hodgkin’s 
lymphoma
5 3.8 126 96.2 131
  Neuroblastoma 6 4.2 138 95.8 144
  Non-heritable 
retinoblastoma
1 3.2 30 96.8 31
  Heritable retinoblastoma 4 2.9 134 97.1 138
  Wilms 7 3.8 177 96.2 184
  Bone sarcoma 1 0.5 197 99.5 198
  Soft tissue sarcoma 11 4.3 242 95.7 253
  Germ cell tumours 8 10.7 67 89.3 75
  Other 5 2.9 168 97.1 173
Age at diagnosis (years)
  Mean 7.3 7.3 7.3
  0–4 64 3.9 1597 96.1 1661
  5–9 43 3.2 1309 96.8 1352
  10–14 57 3.9 1405 96.1 1462
Treatment era
  1940–1969 61 4.6 1268 95.4 1329
  1970–1979 48 3.8 1199 96.2 1247
  1980–1989 36 3.8 905 96.2 941
  1990–2006 19 2.0 939 98.0 958
Years from diagnosis
  Mean 24.7 16.7 17.0
  5–9 36 1.7 2022 98.3 2058
  10–19 33 3.1 1028 96.9 1061
  20–29 33 6.0 515 94.0 548
  30–39 32 7.6 390 92.4 422
  40–49 21 7.6 256 92.4 277
  50–59 8 7.7 96 92.3 104
  60+ 1 5.9 16 94.1 17
Attained age at exit (years)
  Mean 32.0 24.0 24.3
  5–9 7 1.7 409 98.3 416
  10–19 37 2.0 1797 98.0 1834
  20–29 35 3.5 970 96.5 1005
  30–39 34 6.3 502 93.7 536
Continued
Patient characteristic
Respiratory 
death %
other 
death % Total
  40–49 27 7.3 341 92.7 368
  50–59 20 8.4 218 91.6 238
  60+ 4 4.4 86 95.6 90
AML, acute myeloid leukaemia; CNS, central nervous system; PNET, primitive 
neuroectodermal tumour.
Table 1 Continued 
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Pneumonia deaths
Male survivors of adolescent and young adult cancers experienced 
more excess pneumonia mortality compared with females (adjusted 
p heterogeneity=0.0061) (figure 4). Survivors of lung cancer, CNS 
tumours and head and neck cancers experienced the greatest excess 
number of pneumonia deaths at 3.6 (95% CI 0.6 to 6.7), 2.5 (95% 
CI 1.7 to 3.2) and 2.1 (95% CI 0.7 to 3.5), respectively. The excess 
number of pneumonia deaths increased as age at diagnosis increased 
(adjusted p trend=0.0312) and declined among those treated more 
recently (adjusted p trend=0.0083).
Chronic lower respiratory disease deaths
Survivors of lung cancer experienced the greatest excess number 
of deaths at 6.6 (95% CI 2.5 to 10.6) (table 3). AERs increased 
Figure 1 SMRs and AERs per 10 000 person-years for all respiratory mortality in the British Childhood Cancer Survivor Study. P heterogeneity and 
p trend were calculated by using likelihood ratio tests within multivariable Poisson regression models that adjusted for sex, first primary neoplasm 
type, age at diagnosis, treatment era and attained age. Strata with less than five observed events should be interpreted with caution. AER, absolute 
excess risk; AML, acute myeloid leukaemia; CNS, central nervous system; E, expected; O, observed; PNETs, primitive neuroectodermal tumour; SMR, 
standardised mortality ratio. 
Figure 2 SMRs and AERs per 10 000 person-years for pneumonia mortality in the British Childhood Cancer Survivor Study. P heterogeneity and 
p trend were calculated by using likelihood ratio tests within multivariable Poisson regression models that adjusted for sex, first primary neoplasm 
type, age at diagnosis, treatment era and attained age. Strata with less than five observed events should be interpreted with caution. AER, absolute 
excess risk; AML, acute myeloid leukaemia; CNS, central nervous system; E, expected; O, observed; PNETs, primitive neuroectodermal tumours; SMR, 
standardised mortality ratio. 
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with attained age from 0.1 (95% CI −0.1 to 0.4) to 1.3 (95% 
CI 0.2 to 2.3) among those aged 20–29 years and 60+ years, 
respectively (adjusted p trend <0.0001). Survivors diagnosed 
more recently experienced less excess chronic lower respiratory 
disease deaths (adjusted p trend=0.0024).
Fibrosis and pneumonitis deaths
With regards to fibrosis death, female survivors were found to 
experience a greater excess number of deaths than male survi-
vors (adjusted p heterogeneity=0.0040) (table 3). For both 
fibrosis and pneumonitis deaths, the AERs were consistently less 
than one after each specific FPN type, except for fibrosis deaths 
among AML survivors, though only three deaths were observed. 
Finally, the AER increased with increasing attained age for pneu-
monitis deaths (adjusted p trend=0.0078).
dIsCussIon
Compared with the previous literature, our study is by far the 
largest to assess respiratory mortality among 5-year survivors of 
childhood, adolescent and young adult cancers, reporting for the 
first time results for specific types of respiratory death and risks 
beyond 50 years of age. There have been two previous studies 
of survivors of cancer diagnosed in individuals aged at least 
20 years—one included 11 417 5-year survivors and 29 respi-
ratory deaths,14 the other included 1248 5-year survivors and 
7 respiratory deaths,15 and we included 188 697 5-year survivors 
and 1079 respiratory deaths. As a result of these large numbers, 
and our study’s population-based design and long period of 
follow-up, we provide the most comprehensive investigation of 
risks and risk factors for respiratory mortality among childhood, 
adolescent and young adult cancer survivors to date.
Our principal new findings include the following. Among 
survivors of childhood cancer, the greatest excess numbers of 
respiratory deaths were experienced after PNETs of the CNS and 
other CNS tumours at 7.7 and 5.1 extra, respectively. Among 
survivors of adolescent and young adult cancer, the greatest 
excess number of respiratory deaths was experienced after 
lung cancer, leukaemia (excluding AML), AML, head and neck 
and CNS tumours at 11.4, 5.0, 4.8, 4.4 and 4.3 extra, respec-
tively. The excess number of respiratory deaths increased with 
increasing attained age, reaching 6.8 excess deaths among those 
aged 50+ years in the BCCSS, and reaching 2.8 excess deaths 
among those aged 60+ years in the TYACSS cohort. It was reas-
suring that the excess number of respiratory deaths declined 
among those treated more recently in both cohorts, and in each 
cohort, the AER declined to about one excess respiratory death 
among those treated most recently.
Table 2 Study characteristics of the teenage and young adult cancer 
survivor study
Patient characteristic
Respiratory 
death %
other 
death % Total
Overall 1079 3.2 33 101 96.8 34 180
Sex
  Male 479 4.0 11 606 96.1 12 085
  Female 600 2.7 21 495 97.3 22 095
First primary neoplasm 
type
  Breast 135 1.3 10 474 98.7 10 609
  Testicular 98 4.9 1909 95.1 2007
  Cervical 152 5.8 2490 94.3 2642
  Melanoma 25 1.1 2293 98.9 2318
  CNS tumour 141 3.4 3958 96.6 4099
  Hodgkin’s lymphoma 134 4.4 2937 95.6 3071
  Non-Hodgkin’s 
lymphoma
72 4.2 1647 95.8 1719
  Thyroid 13 3.1 402 96.9 415
  Gastrointestinal 47 3.4 1346 96.6 1393
  Soft tissue sarcoma 30 3.4 863 96.6 893
  Ovary 22 3.1 695 96.9 717
  Bladder 30 5.2 552 94.9 582
  Other genitourinary 35 4.1 819 95.9 854
  Head and neck 42 6.1 648 93.9 690
  Leukaemia (excluding 
AML)
25 3.3 743 96.7 768
  Other 26 4.9 501 95.1 527
  Bone tumour 11 3.0 361 97.0 372
  AML 12 5.5 205 94.5 217
  Lung 29 10.1 258 89.9 287
Age at diagnosis (years)
  Mean 33.2 33.1 33.1
  15–19 53 3.8 1360 96.3 1413
  20–24 83 3.4 2326 96.6 2409
  25–29 141 3.0 4584 97.0 4725
  30–34 257 2.8 8924 97.2 9181
  35–39 545 3.3 15 907 96.7 16 452
Treatment era
  1971–1979 459 4.9 8972 95.1 9431
  1980–1989 412 3.3 11 908 96.7 12 320
  1990–1990 169 1.9 8811 98.1 8980
  2000–2006 39 1.1 3410 98.9 3449
Years from diagnosis
  Mean 22.0 14.5 14.8
  5–9 159 1.1 14 235 98.9 14 394
  10–19 280 2.6 10 505 97.4 10 785
  20–29 384 6.3 5722 93.7 6106
  30–39 245 8.9 2500 91.1 2745
  40+ 11 7.3 139 92.7 150
Attained age at 
exit (years)
Continued
Patient characteristic
Respiratory 
death %
other 
death % Total
  Mean 55.2 47.7 47.9
  20–29 20 1.6 1252 98.4 1272
  30–39 105 1.8 5731 98.2 5836
  40–49 229 1.6 14 420 98.4 14 649
  50–59 317 4.2 7177 95.8 7497
  60–69 307 7.7 3661 92.3 3968
  70+ 101 10.5 858 89.5 959
AML, acute myeloid leukaemia; CNS, central nervous system. 
Table 2 Continued 
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Respiratory epidemiology
Figure 3 SMRs and AERs per 10 000 person-years for all respiratory mortality in the Teenage and Young Adult Cancer Survivor Study. P 
heterogeneity and p trend were calculated by using likelihood ratio tests within multivariable Poisson regression models that adjusted for sex, 
first primary neoplasm type, age at diagnosis, treatment era and attained age. Strata with less than five observed events should be interpreted 
with caution. AER, absolute excess risk; AML, acute myeloid leukaemia; CNS, central nervous system; E, expected; O, observed; PNETs, primitive 
neuroectodermal tumour; SMR, standardised mortality ratio.
Figure 4 SMRs and AERs per 10 000 person-years for pneumonia mortality in the Teenage and Young Adult Cancer Survivor Study. P heterogeneity 
and p trend were calculated by using likelihood ratio tests within multivariable Poisson regression models that adjusted for sex, first primary 
neoplasm type, age at diagnosis, treatment era and attained age. Strata with less than five observed events should be interpreted with caution. AER, 
absolute excess risk; AML, acute myeloid leukaemia; CNS, central nervous system; E, expected; O, observed; PNETs, primitive neuroectodermal tumour; 
SMR, standardised mortality ratio 
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Respiratory epidemiology
our findings in relation to previous research
In this study, childhood cancer survivors were seven times 
more at risk of respiratory death than that expected from the 
general population, while adolescent and young adult cancer 
survivors were two times more at risk; these findings broadly 
correspond with previous reports.14–16 However, when assessed 
in more detail, the excess risks for specific types of respiratory 
death varied considerably. Significant excesses were observed for 
pneumonia, fibrosis, pneumonitis and other respiratory deaths 
for childhood cancer survivors, with the SMRs ranging from 
7-fold to 17-fold that expected. Similarly, risks varied among 
adolescent and young adult cancer survivors depending on the 
specific type of respiratory death, although to a lesser extent 
than that observed among childhood cancer survivors. The fact 
that the SMR among childhood cancer survivors was higher than 
the corresponding SMR in adolescents and young adults for each 
type of respiratory death assessed could relate to the increased 
vulnerability of children to radiotherapy, chemotherapy and 
surgery side effects as the child is still growing and developing,17 
while adolescents and young adults generally tolerate acute 
side effects of therapy relatively well.18
In regards to risk factors, the greatest excess numbers of respi-
ratory deaths among survivors of childhood cancer were experi-
enced after CNS PNET and other CNS tumours, and after lung 
cancer, leukaemia (excluding AML), AML, head and neck and 
CNS tumours among survivors of adolescent and young adult 
cancer. The large increased risks observed in these specific FPN 
types could relate to previous cancer treatment.5 19 For example, 
craniospinal irradiation and the use of nitrosureas in CNS survi-
vors can induce pneumonitis and late restrictive lung disease,20 
while restrictive and obstructive lung disease can develop as a 
result of the use craniospinal irradiation, total body irradiation 
or high-dose busulphan in bone marrow transplantation for 
leukaemia survivors.19 21 Other clinical correlations between 
therapeutic agents and respiratory late effects are as follows: 
(1) busulfan, carmustine or lomustine and the development 
of pulmonary fibrosis; (2) bleomycin and the development of 
interstitial pneumonitis, pulmonary fibrosis or acute respiratory 
distress syndrome; (3) irradiation to the axilla, chest, extended 
mantle, mantle, mediastinal, mini-mantle or whole lung, subtotal 
lymphoid irradiation, total body irradiation or total lymphoid 
irradiation and the development of pulmonary fibrosis, inter-
stitial pneumonitis, restrictive lung disease or obstructive lung 
disease; (4) haematopoietic cell transplant with any history of 
graft-versus-host disease and the development of pulmonary 
toxicity, bronchiolitis obliterans, chronic bronchitis or bron-
chiectasis; and (5) thoracic surgery and the development of 
pulmonary dysfunction.22 However, there may be non-treatment 
factors that contribute to respiratory mortality. This is partic-
ularly apparent for chronic lower respiratory disease deaths 
in lung cancer survivors, which accounted for 55% (16/29) of 
the observed excess respiratory deaths in this FPN type, as it is 
hypothesised that these diseases share underlying host suscepti-
bility factors.23 Similarly, the fact that over 60% (46/77) of the 
pneumonia deaths in childhood cancer survivors occurred in 
survivors of CNS tumours or CNS PNET suggests an increased 
risk of aspiration pneumonia, which may be linked to a weaker 
cough reflex due to chronic neurological deficits.24
Another interesting finding from our study is that there were 
an increasing number of excess respiratory deaths as survivors 
aged. These findings may relate to the fact that respiratory death 
is among the more common causes of death among mature 
members of the general population. Consequently, because the 
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expected number of deaths is substantial, even a modest multi-
plicative excess risk will result in substantial excess numbers of 
death.
Nonetheless, it was reassuring that the excess number of respi-
ratory deaths declined among those treated more recently in 
both cohorts. Such declines could be due to changes in cancer 
treatments, with the newer treatment regimens designed to 
reduce radiotherapy and chemotherapy exposures while main-
taining long-term, disease-free survival3 25; moving forward, 
continued improvement is a reasonable expectation, especially 
with the use of proton beam therapy, which will further limit 
the dose of radiotherapy scatter to the lungs. Other potential 
contributors include the increased surveillance of late effects 
through regular follow-up and screening, as well as increased 
supportive care with improved antiviral and antifungal agents 
that may limit the severity of lung infections and complications 
compared with previously.3 25 26
Clinical implications
Although the findings presented in this study provide reliable 
(based on large numbers) and unbiased (population-based 
design) evidence on respiratory mortality risks, it is important 
that these results also inform clinicians and the vulnerable 
subgroups of survivors identified about the risks of respiratory 
morbidity. At-risk survivors and survivors with reduced lung 
reserve/function or abnormal/damaged lung tissues from cancer 
treatment should be monitored for chronic cough or dyspnoea 
through yearly pulmonary exams18 22 and should be aware of 
their susceptibility to further insults from recurrent respiratory 
infections (eg, pneumonia), lifestyle factors (eg, smoking27 28 or 
occupational exposure to toxic fumes/substances29) and other 
medical interventions (eg, exposure to high oxygen concentra-
tion with anaesthesia30–32); such subsequent insults can lead to 
further significant deterioration in lung function and reserve, 
respiratory failure and death. Furthermore, pneumococcal 
vaccination should be considered an important intervention 
for childhood, adolescent and young adult cancer survivors as 
pneumonia was the most common form of respiratory death in 
all groups, with substantial excess risks observed compared with 
that expected; although influenza-related deaths were observed 
less frequently in this study, influenza may act as a precursor to 
more serious respiratory conditions like pneumonia, and thus 
influenza vaccination may also be a useful preventative strategy 
for at-risk survivors. Finally, as the risks of respiratory mortality 
varied depending on the age at diagnosis of the survivor and 
the type of death being investigated, clinical follow-up guide-
lines should be refined in order to provide more accurate sugges-
tions for survivors depending on whether they are a childhood, 
adolescent or young adult survivor, while interventions relating 
to specific respiratory complications should be developed.
limitations
The first limitation of our study is that we only included individ-
uals who survived at least 5 years after their cancer diagnosis, and 
thus the risks presented in this study are not representative of the 
risks for childhood, adolescent and young adult cancer survi-
vors overall. Additionally, our calculations of SMRs and AERs 
are likely an underestimation of the multiplicative and additive 
excesses as competing causes of death are more common in our 
study population than in the general population33; as there is no 
accurate way to adjust for this bias,33 we acknowledge that our 
findings are likely to be conservative. Another limitation is that 
our study faced data sparsity for some stratifications; despite 
this being the largest study of respiratory mortality among such 
survivors, the outcome in question remains rare and thus our 
results with less than five observed events should be interpreted 
with caution. Furthermore, due to the fact that we determined 
respiratory deaths based on the underlying cause of death coded 
on the death certificate, there is possibly misclassification in our 
data as the underlying cause of death has imperfect accuracy.34–36 
This study also lacked detailed treatment information, which 
prevented any examination of dose response patterns or treat-
ment interactions. Information was also not available on lifestyle 
factors, making it impossible to assess the relative importance of 
smoking status, occupational hazards and other environmental 
factors. Finally, our findings suggest a significant increase in 
excess respiratory deaths as age increases. Although these find-
ings provide important information for current survivors aged at 
least 50 years, it will be important to reassess our findings to see 
whether the risks remain consistent as younger survivors reach 
this age milestone since the cancer profile of 5 year survivors and 
treatment have changed over time. Similarly, it will be important 
to reinvestigate temporal trends in late respiratory mortality 
risks with additional follow-up in order to determine whether 
those most recently diagnosed remain with decreased risks.
ConClusIons
This large-scale, population-based study provides evidence that 
survivors of childhood, adolescent and young adult cancers are 
at an increased risk of respiratory death, compared with that 
expected, both overall and for specific types of respiratory 
death. Although we report appreciable excess risks for respira-
tory death among specific FPN types and survivors aged over 
50 years, there is evidence of a reduction in the excess number of 
respiratory deaths among individuals more recently diagnosed. 
These findings substantially advance the current knowledge on 
respiratory late effects among childhood, adolescent and young 
adult cancer survivors and will be useful for both survivors and 
those involved in their clinical management and follow-up.
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